BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the âCompanyâ), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation.
Related Questions
How will the receipt of multiple patent allowances for SCP-111 affect SCPH's shortâterm stock price?
What is the expected timeline for the supplemental NDA filing and subsequent FDA review of SCP-111?
How strong are these patents likely to be against potential challenges or designâaround efforts from competitors?
What market size and revenue uplift does management anticipate from the SCP-111 formulation once commercialized?
Is there any indication of licensing or partnership opportunities tied to the newly allowed patents?
Could the patent news lead to increased R&D spending or capital raises that might dilute existing shareholders?
How might the patent allowances influence analyst coverage, target price revisions, or institutional sentiment toward SCPH?
Are there any regulatory or reimbursement hurdles specific to the SCP-111 formulation that could impact its commercial rollout?
Will the new patents extend the company's exclusivity period and how does that compare to existing competitors' furosemide products?
What is the potential impact on the company's pipeline valuation if SCP-111 proves successful and funds further development projects?